59 results
8-K
EX-99.1
MAIA
MAIA Biotechnology, Inc.
4 Jun 24
Regulation FD Disclosure
4:06pm
targeted clinical milestones within reach. THIO-101 topline data in mid-2024; long-term data in 2nd half of 2024 Multiple potential pathways to FDA … No recurrence after long-term follow- due to THIO Rechallenge with up 500 5x more lung cancer cells with Anticancer immune memory has been 400 no additional
8-K
EX-99.2
MAIA
MAIA Biotechnology, Inc.
4 Jun 24
Regulation FD Disclosure
4:06pm
efficacious combination by Topline data expected mid-2024; long-term data on tumor type and expand into pivotal trials (12+ second half of 2024 possible
8-K
EX-99.1
m3vesv
6 Mar 24
Other Events
8:00am
8-K
EX-99.1
xv1y hibf7kf9
23 Feb 24
MAIA Biotechnology Completes Enrollment in THIO-101 Phase 2 Clinical Trial for Non-Small Cell Lung Cancer
4:17pm
8-K
EX-99.1
m6ndmr1i pzd0csqu
18 Jan 24
MAIA Biotechnology Provides Positive Phase 2 Clinical Updates for Lead Anticancer Agent and Outlines Targeted Milestones for 2024
6:01am
8-K
EX-99.1
0hy82cjx
7 Nov 23
MAIA Biotechnology Reports Third Quarter 2023 Financial Results and Highlights Recent Development Progress for Anticancer Asset THIO
8:05am
8-K
EX-99.1
stfo mufjoe
28 Sep 23
MAIA Biotechnology Announces Share Repurchase Program
5:12pm
8-K
EX-10.1
pnhala4d9y 5rf
1 Sep 23
Entry into a Material Definitive Agreement
4:45pm
FWP
lhkj9x0v5eu8 fvxgk
11 Jul 23
Free writing prospectus
12:42pm
FWP
4yvdn63v
9 Jun 23
Free writing prospectus
6:47am
DRS
zrwpphql o87lvb
1 Jun 23
Draft registration statement
12:00am